Pricing Log in Create free account

Aclaris Therapeutics, Inc. (ACRS) vs VectivBio Holding AG (VECT)

Aclaris Therapeutics, Inc. and VectivBio Holding AG are both Biotechnology companies. Aclaris Therapeutics, Inc. and VectivBio Holding AG are of similar size ($545.5M and $513.7M). VectivBio Holding AG has the higher net margin (0.00% vs −921.5%) and the higher return on invested capital (0.00% vs −163.4%). Across the 12 metrics below, Aclaris Therapeutics, Inc. leads on 8 and VectivBio Holding AG on 4.

Valuation

Metric ACRS VECT Biotechnology median
P/E n/m n/m 8.50
P/S 56.96 n/m 9.71
P/B 3.76 3.94 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 47.13 n/m 9.21
Earnings yield (17.68%) (27.42%) (33.15%)
Free cash flow yield (13.28%) (21.00%) (25.50%)

Profitability

Metric ACRS VECT Biotechnology median
Gross margin 12.90% — 65.16%
Operating margin (1,050.16%) — 0.00%
Net margin (921.50%) 0.00% 0.00%
Free cash flow margin (756.50%) 0.00% 0.00%
Return on equity (59.10%) (147.18%) (56.36%)
Return on assets (41.07%) (111.86%) (48.04%)
Return on invested capital (163.35%) 0.00% 0.00%

Growth

Metric ACRS VECT Biotechnology median
Revenue growth (TTM) (51.04%) — 6.02%
EPS growth (last fiscal year) 69.01% 34.37% 30.26%
Revenue growth, 5-year CAGR 3.84% — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ACRS VECT Biotechnology median
Debt to equity 0.00 0.05 0.00
Current ratio 3.46 9.14 4.72
Net debt to EBITDA 1.20 2.63 0.96

Dividend

Metric ACRS VECT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACRS VECT Biotechnology median
Market cap 513.72m 545.50m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack